X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (25142) 25142
Newsletter (5685) 5685
Newspaper Article (377) 377
Book Chapter (101) 101
Dissertation (54) 54
Transcript (36) 36
Conference Proceeding (22) 22
Magazine Article (17) 17
Publication (16) 16
Report (14) 14
Book / eBook (10) 10
Reference (8) 8
Book Review (5) 5
Government Document (5) 5
Web Resource (4) 4
Streaming Video (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
anthracyclines (24772) 24772
cancer (13201) 13201
humans (11819) 11819
chemotherapy (9192) 9192
research (7603) 7603
female (7027) 7027
doxorubicin (6947) 6947
oncology (6562) 6562
breast cancer (5087) 5087
care and treatment (5048) 5048
analysis (4637) 4637
drugs (4571) 4571
animals (4355) 4355
male (3938) 3938
middle aged (3851) 3851
adult (3458) 3458
pharmacology & pharmacy (3218) 3218
anthracycline (3196) 3196
drug delivery systems (3135) 3135
aged (3105) 3105
oncology, experimental (3058) 3058
breast neoplasms - drug therapy (2945) 2945
apoptosis (2799) 2799
health aspects (2767) 2767
vehicles (2665) 2665
antineoplastic combined chemotherapy protocols - therapeutic use (2639) 2639
physical fitness (2546) 2546
nanoparticles (2451) 2451
cell line, tumor (2429) 2429
doxorubicin - administration & dosage (2406) 2406
doxorubicin - pharmacology (2345) 2345
cardiotoxicity (2249) 2249
tumors (2224) 2224
therapy (2221) 2221
mice (2209) 2209
treatment outcome (2160) 2160
drug therapy (1971) 1971
medicine & public health (1862) 1862
cyclophosphamide (1857) 1857
universities and colleges (1759) 1759
breast neoplasms - pathology (1652) 1652
metastasis (1643) 1643
hematology (1597) 1597
toxicity (1537) 1537
biochemistry & molecular biology (1525) 1525
drug resistance (1486) 1486
antineoplastic agents - therapeutic use (1416) 1416
prognosis (1374) 1374
adriamycin (1347) 1347
antineoplastic agents - pharmacology (1342) 1342
expression (1286) 1286
anthracyclines - adverse effects (1267) 1267
antibiotics, antineoplastic - pharmacology (1219) 1219
paclitaxel (1213) 1213
rats (1209) 1209
anthracyclines - therapeutic use (1202) 1202
neoplasms - drug therapy (1201) 1201
cancer therapies (1190) 1190
doxorubicin - chemistry (1187) 1187
clinical trials (1182) 1182
doxorubicin - therapeutic use (1179) 1179
medical research (1177) 1177
cytotoxicity (1149) 1149
antineoplastic combined chemotherapy protocols - adverse effects (1142) 1142
survival (1134) 1134
antibiotics, antineoplastic - administration & dosage (1120) 1120
dna (1120) 1120
anthracyclines - administration & dosage (1110) 1110
dose-response relationship, drug (1110) 1110
proteins (1108) 1108
cells (1101) 1101
leukemia (1077) 1077
cell survival - drug effects (1072) 1072
risk factors (1069) 1069
antineoplastic agents - adverse effects (1057) 1057
in-vitro (1056) 1056
apoptosis - drug effects (1044) 1044
disease-free survival (1031) 1031
women (1019) 1019
adolescent (1012) 1012
doxorubicin - adverse effects (1007) 1007
retrospective studies (993) 993
breast-cancer (991) 991
chemistry, multidisciplinary (988) 988
lymphomas (981) 981
genetic aspects (933) 933
gene expression (911) 911
medicine, experimental (904) 904
aged, 80 and over (900) 900
cardiac & cardiovascular systems (899) 899
oxidative stress (898) 898
drug delivery (897) 897
cell biology (889) 889
drug-delivery (887) 887
cardiomyopathy (884) 884
trastuzumab (880) 880
antineoplastic agents - administration & dosage (864) 864
hematology, oncology and palliative medicine (858) 858
medical colleges (852) 852
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (30881) 30881
Japanese (266) 266
French (146) 146
German (104) 104
Russian (81) 81
Chinese (58) 58
Polish (49) 49
Portuguese (36) 36
Czech (34) 34
Spanish (32) 32
Italian (30) 30
Slovak (10) 10
Hungarian (9) 9
Danish (6) 6
Turkish (4) 4
Dutch (3) 3
Finnish (3) 3
Korean (3) 3
Persian (2) 2
Serbian (2) 2
Arabic (1) 1
Hebrew (1) 1
Indonesian (1) 1
Lithuanian (1) 1
Norwegian (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of the American College of Cardiology, ISSN 0735-1097, 10/2017, Volume 70, Issue 16, p. C57
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 08/2017, Volume 259, pp. e184 - e184
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 08/2017, Volume 259, pp. e27 - e27
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 08/2017, Volume 259, pp. e178 - e179
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 08/2017, Volume 259, pp. e128 - e128
Journal Article
Journal of cardiac failure, ISSN 1071-9164, 10/2017, Volume 23, Issue 10, p. S81
Journal Article
Circulation, ISSN 0009-7322, 06/2015, Volume 131, Issue 22, pp. 1946 - 1949
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2017, Volume 76, Issue 6, pp. AB104 - AB104
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 10/2015, Volume 66, Issue 16, p. C51
Journal Article
Antioxidants & redox signaling, ISSN 1523-0864, 2013, Volume 18, Issue 8, pp. 899 - 929
Significance: Anthracyclines (doxorubicin, daunorubicin, or epirubicin) rank among the most effective anticancer drugs, but their clinical usefulness is... 
Forum Review Articles | DOXORUBICIN-INDUCED CARDIOTOXICITY | ADVANCED BREAST-CANCER | SPONTANEOUSLY HYPERTENSIVE-RATS | MANGANESE SUPEROXIDE-DISMUTASE | BIOCHEMISTRY & MOLECULAR BIOLOGY | ADRIAMYCIN-INDUCED CARDIOMYOPATHY | ACUTE LYMPHOBLASTIC-LEUKEMIA | ENDOCRINOLOGY & METABOLISM | SALICYLALDEHYDE ISONICOTINOYL HYDRAZONE | MITOCHONDRIAL CALCIUM HOMEOSTASIS | CONGESTIVE-HEART-FAILURE | FREE-RADICAL FORMATION | Anthracyclines - adverse effects | Reactive Oxygen Species - metabolism | Antioxidants - chemistry | Oxidative Stress | Humans | Metals - adverse effects | Razoxane - pharmacology | Anthracyclines - pharmacology | Antineoplastic Agents - adverse effects | Cardiotonic Agents - adverse effects | Myocardium - metabolism | Antineoplastic Agents - pharmacology | Razoxane - chemistry | Chelating Agents - adverse effects | Anthracyclines - chemistry | Oxidation-Reduction | Signal Transduction | Chelating Agents - chemistry | Cardiotonic Agents - chemistry | Antioxidants - pharmacology | Cardiotonic Agents - pharmacology | Chelating Agents - pharmacology | Antineoplastic Agents - chemistry | Razoxane - adverse effects | Heart - drug effects | Complications and side effects | Oxidative stress | Anthracyclines | Oxidation-reduction reaction | Chemical reactions | Dosage and administration | Research | Index Medicus | Forum Review
Journal Article
Cochrane library, ISSN 1465-1858, 2016, Volume 2020, Issue 6, p. CD005008
Background This review update has been managed by both the Childhood Cancer and Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Groups. The use of... 
Heart | 'ORPHAN' TOPICS CURRENTLY BEING ADDRESSED | Supportive care: therapy-related side effects during treatment | Anthracyclines | Supportive care: anthracycline cardiotoxicity | Late effects: therapy-related side effects after treatment | Techniques to modulate the effects of chemotherapy and/or radiotherapy | Antibiotics, Antineoplastic | Cardiac Output, Low | Neoplasms | Randomized Controlled Trials as Topic | Heart Diseases | Child health | Techniques to modulate the effects of chemotherapy & radiotherapy | Medicine General & Introductory Medical Sciences | General cancer treatments | Cancer | ADJUVANT CHEMOTHERAPY | SOFT-TISSUE SARCOMAS | Humans | CLINICAL HEART-FAILURE | prevention & control | PHASE-III TRIAL | Anthracyclines [administration & dosage; adverse effects] | MEDICINE, GENERAL & INTERNAL | Cardiac Output, Low [chemically induced | HIGH-RISK | Heart [drug effects] | METASTATIC BREAST-CANCER | ACUTE LYMPHOBLASTIC-LEUKEMIA | DOXORUBICIN CARDIOTOXICITY | Heart Diseases [chemically induced] | Adult | NON-HODGKINS-LYMPHOMA | DENSE SEQUENTIAL CHEMOTHERAPY | Neoplasms [drug therapy] | Antibiotics, Antineoplastic [administration & dosage; adverse effects] | Child | Anthracyclines - adverse effects | Cardiac Output, Low - chemically induced | Cardiac Output, Low - prevention & control | Antibiotics, Antineoplastic - adverse effects | Neoplasms - drug therapy | Antibiotics, Antineoplastic - administration & dosage | Anthracyclines - administration & dosage | Heart - drug effects | Heart Diseases - chemically induced
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 09/2015, Volume 213, pp. e18 - e18
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 09/2015, Volume 213, pp. e15 - e15
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 09/2015, Volume 213, pp. e34 - e34
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 09/2015, Volume 213, pp. e126 - e127
Journal Article
Nature medicine, ISSN 1546-170X, 2006, Volume 13, Issue 1, pp. 54 - 61
Anthracyclin-treated tumor cells are particularly effective in eliciting an anticancer immune response, whereas other DNA-damaging agents such as etoposide and... 
MEDICINE, RESEARCH & EXPERIMENTAL | CLEARANCE | DENDRITIC CELLS | BIOCHEMISTRY & MOLECULAR BIOLOGY | TUMOR | CHAPERONE | CELL BIOLOGY | DYING CELLS | APOPTOTIC CELLS | SURFACE CALRETICULIN | ENDOPLASMIC-RETICULUM | BINDING | ANTIGEN | Apoptosis - drug effects | Colonic Neoplasms - drug therapy | Dendritic Cells - immunology | Electrophoresis, Gel, Two-Dimensional | Immunoblotting | Antineoplastic Agents - therapeutic use | Protein Transport - drug effects | Calreticulin - genetics | Colonic Neoplasms - metabolism | Cell Cycle Proteins - antagonists & inhibitors | RNA Interference | Anthracyclines - pharmacology | Neoplasms, Experimental - immunology | Calreticulin - metabolism | Antigens, Differentiation - metabolism | Antineoplastic Agents - pharmacology | Cell Membrane - metabolism | Protein Phosphatase 1 | Cell Membrane - drug effects | Mitomycin - therapeutic use | Cell Cycle Proteins - metabolism | Phagocytosis - immunology | Etoposide - pharmacology | Etoposide - therapeutic use | Recombinant Proteins - pharmacology | Mitomycin - pharmacology | Animals | Apoptosis - immunology | Mice, Nude | Colonic Neoplasms - pathology | Cell Line, Tumor | Cell Membrane - immunology | Mice | Mice, Inbred BALB C | Anthracyclines - therapeutic use | Calreticulin - immunology | Neoplasms, Experimental - metabolism | Neoplasms, Experimental - drug therapy | Chemotherapy | Immunology | DNA damage | Rodents | Cancer | Apoptosis | Tumors | Antigens, Differentiation | Cell Membrane | Anthracyclines | Dendritic Cells | Recombinant Proteins | Life Sciences | Calreticulin | Neoplasms, Experimental | Mitomycin | Etoposide | Antineoplastic Agents | Protein Transport | Phagocytosis | Cell Cycle Proteins | Colonic Neoplasms
Journal Article
Circulation research, ISSN 0009-7330, 01/2018, Volume 122, Issue 2, pp. 188 - 190
Journal Article
Cochrane library, ISSN 1465-1858, 2011, Volume 2016, Issue 9, p. CD003917
Background Anthracyclines are among the most effective chemotherapeutic agents in the treatment of numerous malignancies. Unfortunately, their use is limited... 
'ORPHAN' TOPICS CURRENTLY BEING ADDRESSED | Anthracyclines | Infections in neutropenic cancer patients | Razoxane | Supportive care: therapy‐related side effects during treatment | Supportive care: anthracycline cardiotoxicity | Antibiotics, Antineoplastic | Neoplasms | Randomized Controlled Trials as Topic | Cardiotonic Agents | Complementary & alternative medicine | Heart Diseases | Child health | Techniques to modulate the effects of chemotherapy & radiotherapy | Medicine General & Introductory Medical Sciences | Late effects: therapy‐related side effects after treatment | General cancer treatments | Cytoprotection | Cancer | Antineoplastic [adverse effects] | Anthracyclines [adverse effects] | ADVANCED BREAST-CANCER | RISK-FACTORS | Cardiotonic Agents [therapeutic use] | Humans | DOXORUBICIN-CONTAINING THERAPY | INDUCED CARDIAC TOXICITY | MEDICINE, GENERAL & INTERNAL | INDUCED CARDIOTOXICITY | Antibiotics | ACUTE LYMPHOBLASTIC-LEUKEMIA | ADRIAMYCIN-INDUCED CARDIOMYOPATHY | PROSPECTIVE RANDOMIZED TRIAL | NON-HODGKIN-LYMPHOMA | HIGH-DOSE CHEMOTHERAPY | Heart Diseases [chemically inducedprevention & control]; Neoplasms [drug therapy] | Anthracyclines - adverse effects | Cardiotonic Agents - therapeutic use | Antibiotics, Antineoplastic - adverse effects | Heart Diseases - prevention & control | Razoxane - therapeutic use | Heart Diseases - chemically induced | Neoplasms - drug therapy
Journal Article